FDA approves bemotrizinol for U.S. sunscreens, opening the door to newer, broad-spectrum UV protection
The FDA approved bemotrizinol as a new OTC sunscreen ingredient, the first expansion in over 25 years, allowing up to 6% in U.S. formulations and promising broader, photostable UVA/UVB protection with low systemic absorption and improved formulation options.
- New active ingredient: bemotrizinol (Parsol Shield) authorized for OTC sunscreens up to 6%.
- Regulatory milestone: First modern UV filter cleared via the OMOR/MUsT process under updated FDA standards.
- Market timing and exclusivity: DSM will market it as Parsol Shield with roughly an 18‑month exclusivity window; products may arrive in 2026.
Key information
The U.S. Food and Drug Administration has authorized bemotrizinol for use in over‑the‑counter sunscreens at concentrations up to 6% under the modern OTC monograph review process. See the FDA announcement for details.
This approval followed a modern review under the OTC Monograph Order Request (OMOR) pathway, becoming the first new filter to meet the agency’s updated safety standards in decades (see the review).
DSM Nutritional Products will market the ingredient as Parsol Shield and is expected to have about an 18‑month exclusivity period before other makers can use the filter; early products could reach U.S. shelves in 2026 (see FDA materials).
What bemotrizinol is
Bemotrizinol (often abbreviated BEMT) is a modern organic UV filter used for years in Europe, Canada, Australia and parts of Asia. It is photostable—resisting breakdown in sunlight—and provides truly broad‑spectrum protection against both UVA and UVB rays. For technical background and comparative performance, see the medical review.
FDA action and regulatory context
Until this decision, the FDA’s list of ingredients judged generally recognized as safe and effective (GRASE) had not expanded in more than two decades. The agency used the OMOR and MUsT (maximal usage trial) frameworks to require modern human safety data focused on systemic absorption.
Bemotrizinol completed that process and met the FDA’s safety standards, including demonstrations of low plasma absorption and minimal irritation in clinical studies (see the FDA explanation and the review).
“We’re continuing to modernize the regulation of sunscreen and other over‑the‑counter drug products,” FDA Commissioner Marty Makary, MD, MPH, said. The Office of Nonprescription Drugs’ acting director Karen Murry, MD, called bemotrizinol “a welcome addition” and noted an intent to accelerate other ingredient reviews (see the FDA press release).
DSM, Parsol Shield and market rollout
DSM Nutritional Products LLC (part of DSM‑Firmenich) sponsored the OMOR for bemotrizinol at up to 6% and will brand the ingredient as Parsol Shield in the U.S. Subject to formulation work and labeling, retail products could appear as early as 2026.
Under current guidance DSM is expected to hold an exclusivity window of roughly 18 months before other manufacturers can incorporate bemotrizinol under the monograph terms (see FDA materials and industry reports and the background review).
Safety, absorption and irritation profile
The FDA evaluated human pharmacokinetic studies showing bemotrizinol rarely exceeded the agency’s plasma threshold of 0.5 ng/mL after topical use, supporting a finding of low systemic absorption. Reported adverse events were few and mostly mild; skin irritation at tested concentrations was uncommon.
International experience—years of use across Europe, Canada, Australia and other markets—adds to the evidence supporting a favorable safety and efficacy profile (see the peer review and the FDA release).
Why this change matters
For decades U.S. consumers had fewer sunscreen ingredient choices than people abroad. Bemotrizinol’s approval signals a shift toward modernized review standards and could enable formulators to deliver sunscreens with better UVA coverage, improved cosmetic feel, and greater photostability—benefits for everyday users and for those who work outdoors.
Public health advice remains unchanged: use broad‑spectrum sunscreen with SPF 15 or higher, apply liberally, reapply every two hours, and combine sunscreen with clothing and shade (see the FDA Q&A).
How bemotrizinol will appear to shoppers
In the U.S., bemotrizinol will be listed by its chemical name on the Drug Facts panel even if marketing highlights the name Parsol Shield. The monograph caps concentration at 6%—matching Canada and below the 10% used in some other regions. Expect manufacturers to promote broad‑spectrum claims and improved wear or feel, but standard sun‑safety application practices still apply (see FDA press materials).
Implications for Walla Walla, Washington
Local effects in Walla Walla will likely be modest but positive across economic, political and social dimensions.
Economic impact
Retailers and pharmacies could see a summer sales boost when bemotrizinol products arrive. Early DSM exclusivity may limit brand variety at first, but demand for higher‑performance sunscreens should grow, especially during tourism and outdoor-event seasons.
Political consequences
Conservative readers who favor regulatory reform may view the decision as evidence the FDA can move faster while maintaining safety standards. Local officials may cite the approval when discussing outdoor event guidance or procurement policies.
Social effects
Walla Walla’s active outdoor community—hikers, winery workers, river users and youth sports participants—may welcome another sunscreen option that combines broad coverage with a cosmetically acceptable feel. Employers with outdoor workers might add these products to safety plans.
Cultural relevance
The region’s outdoor lifestyle and tourism culture value practical, reliable sun protection. Bemotrizinol’s photostability and broad coverage align with preferences for products that last through long outdoor days.
Practical applications for residents
When bemotrizinol products hit shelves, shoppers should:
- Look for “broad‑spectrum” labeling and SPF 15 or higher (SPF 30 recommended for extended exposure).
- Apply liberally, reapply every two hours or after swimming/sweating, and use protective clothing and shade.
- Check local clinics and pharmacies for information about product availability and suitability for sensitive skin.
Sources and further reading
- FDA press announcement on expanding sunscreen active ingredient list
- Peer‑reviewed review on U.S. sunscreen regulation and modern filters
- FDA Q&A on the OTC sunscreen monograph and deemed final order
- Industry and rollout reporting (video briefing)
Reporting by Times Media Service.
